<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7048954/results/search/disease/results.xml">
  <result pre="expanded sensitivity for HCV genotypes and resistance to some common" exact="viral" post="mutations. The results also suggest that further study of"/>
  <result pre="the development of new antiviral agents. Keywords porphyrins antiviral agents" exact="hepatitis" post="C virus hepatitis C genotype fig-count: table-count: ref-count: page-count:"/>
  <result pre="new antiviral agents. Keywords porphyrins antiviral agents hepatitis C virus" exact="hepatitis" post="C genotype fig-count: table-count: ref-count: page-count: Introduction Chronic hepatitis"/>
  <result pre="C virus hepatitis C genotype fig-count: table-count: ref-count: page-count: Introduction" exact="Chronic" post="hepatitis C virus, (HCV, Hepacivirus) infection is a serious"/>
  <result pre="virus hepatitis C genotype fig-count: table-count: ref-count: page-count: Introduction Chronic" exact="hepatitis" post="C virus, (HCV, Hepacivirus) infection is a serious health"/>
  <result pre="table-count: ref-count: page-count: Introduction Chronic hepatitis C virus, (HCV, Hepacivirus)" exact="infection" post="is a serious health issue worldwide. In spite of"/>
  <result pre="serious health issue worldwide. In spite of potent antiviral agents," exact="chronic" post="infection can still lead to decompensated cirrhosis and hepatocellular"/>
  <result pre="health issue worldwide. In spite of potent antiviral agents, chronic" exact="infection" post="can still lead to decompensated cirrhosis and hepatocellular carcinoma"/>
  <result pre="potent antiviral agents, chronic infection can still lead to decompensated" exact="cirrhosis" post="and hepatocellular carcinoma (HCC).1 Recent development of multiple antiviral"/>
  <result pre="agents, chronic infection can still lead to decompensated cirrhosis and" exact="hepatocellular carcinoma" post="(HCC).1 Recent development of multiple antiviral drugs that offer"/>
  <result pre="chronic infection can still lead to decompensated cirrhosis and hepatocellular" exact="carcinoma" post="(HCC).1 Recent development of multiple antiviral drugs that offer"/>
  <result pre="is still useful for understanding related Flaviviruses such as Dengue," exact="Yellow fever," post="West Nile and Zika.3 These pathogens still present formidable"/>
  <result pre="formidable treatment challenges. The HCV NS3-4A protease-helicase is an attractive" exact="viral" post="target for antiviral drugs. Enzymatically, the complex performs crucial"/>
  <result pre="with wide genotypic activity, yet they still have issues with" exact="viral" post="resistance and treatment versatility.11–17 Iron protoporphyrin (heme) and structurally"/>
  <result pre="by the FDA for use in patients during attacks of" exact="acute" post="porphyria. The MPPs share many of the chemical properties"/>
  <result pre="Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT), and Moloney murine" exact="leukemia" post="virus reverse transcriptase (Gibco/BRL Life Technologies, Gaithersburg, MD) were"/>
  <result pre="(FRET) probes were purchased from AnaSpec, Fremont, CA. Antibodies All" exact="secondary" post="antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,"/>
  <result pre="sub-genomic HCV RNA (genotype 1b) was used as described.22,23 The" exact="infectious" post="HCV cell culture (HCV cc) strain (J6JFH) as described24"/>
  <result pre="counting and trypan blue staining.28 RNA Isolation and Real-Time RT-PCR" exact="Total" post="RNA was extracted from cells using Trizol reagent (Invitrogen),"/>
  <result pre="(AnaSpec, Fremont, CA) using FRET assays.25,28 Wide (591 nm/622 nm)" exact="short" post="(490nm/520nm), or narrow (340nm/490nm) wavelengths for excitation/emission were used"/>
  <result pre="quantities of porphyrin or control vehicle only. Forty-eight hr later," exact="total" post="RNA was extracted using Trizol reagent and the amount"/>
  <result pre="both enzymatic inhibition of the NS34A protease and attenuation of" exact="viral" post="replication in cell-free and whole-cell assays, respectively. Background fluorescence"/>
  <result pre="= 1.83. (C). Western Blots for HCV proteins after HCV" exact="infection" post="of Huh 7.5 or Huh 5.15NS replicon cells. Log-phase,"/>
  <result pre="(10 µM) for 48 hrs. Cells were then lysed and" exact="viral" post="protein expression evaluated on WB as described in methods."/>
  <result pre="as effective as protoporphyrin for anti-protease activity or inhibition of" exact="viral" post="replication although mesoporphyrin did show appreciable anti-NS3-4A and intracellular"/>
  <result pre="protease activity were conducted as described in methods. Right Panels." exact="Secondary" post="plots of Km/V (slope) versus MPP concentration were used"/>
  <result pre="benefit drug modeling for other serine-activated proteases. HCV has high" exact="viral" post="sequence variability, multiple genotypes, and an error-prone RNA polymerase"/>
  <result pre="coverage, especially for those treatment-experienced individuals and for some resistant" exact="infections" post="with RAS mutations; however, issues such as availability, tolerability,"/>
  <result pre="agents as well as highly specific compounds capable of targeting" exact="viral" post="enzymes.18 While a wide variety of synthetic MP and"/>
  <result pre="and related MPPs appear to extend beyond the inhibition of" exact="viral" post="replication. Heme and ZnPP were shown to rescue innate"/>
  <result pre="of mitochondrial antiviral signaling protein (MAVS), thus enhancing innate immune" exact="type I" post="interferon response.28 Related pathogenic Flaviviruses such as Dengue (DENV),"/>
  <result pre="immune type I interferon response.28 Related pathogenic Flaviviruses such as" exact="Dengue" post="(DENV), West Nile, and Yellow Fever share important structural"/>
  <result pre="pathogenic Flaviviruses such as Dengue (DENV), West Nile, and Yellow" exact="Fever" post="share important structural and enzymatic properties with HCV. For"/>
  <result pre="approval of a specific anti-dengue drug although antiviral therapy in" exact="acute" post="infection may reduce the risk for severe DENV.45 However,"/>
  <result pre="of a specific anti-dengue drug although antiviral therapy in acute" exact="infection" post="may reduce the risk for severe DENV.45 However, Tseng"/>
  <result pre="biliverdin or CoPP treatment of infected DENV cells restored innate" exact="type I" post="interferon signaling similar to our results with HCV.28 Taken"/>
  <result pre="and SnPP, were equally active against four of the major" exact="viral" post="genotype enzyme constructs, ie 1A, 1B, 2A, and 3A,"/>
  <result pre="used to quantify the intracellular activities of the MPPs. However," exact="viral" post="synthesis in replicon cells is known to be affected"/>
  <result pre="enzymatic assays. Thus, it is important to note that the" exact="lower" post="levels of ZnPP found to be effective in vitro"/>
  <result pre="effective in vitro can be achieved in cells during some" exact="disease" post="states. Normally ZnPP is present at about 0.5 µM"/>
  <result pre="the University of Iowa (WNS), and the Doriann Foundation for" exact="hepatitis" post="research University of Iowa (WNS). Abbreviations abs, absorbance; BR,"/>
  <result pre="inhibit HCV replication by 50%; FRET, fluorescence energy transfer; HCV," exact="Hepatitis" post="C virus; HCVcc, Hepatitis C virus cell culture; HO,"/>
  <result pre="50%; FRET, fluorescence energy transfer; HCV, Hepatitis C virus; HCVcc," exact="Hepatitis" post="C virus cell culture; HO, heme oxygenase; IC50, concentration"/>
  <result pre="interest in this work. References References 1.TholeyDM, AhnJ. Impact of" exact="hepatitis" post="C virus infection on hepatocellular carcinoma. Gastroenterol Clin North"/>
  <result pre="this work. References References 1.TholeyDM, AhnJ. Impact of hepatitis C" exact="virus infection" post="on hepatocellular carcinoma. Gastroenterol Clin North Am. 2015;44(4):761–773. doi:10.1016/j.gtc.2015.07.00526600218"/>
  <result pre="work. References References 1.TholeyDM, AhnJ. Impact of hepatitis C virus" exact="infection" post="on hepatocellular carcinoma. Gastroenterol Clin North Am. 2015;44(4):761–773. doi:10.1016/j.gtc.2015.07.00526600218"/>
  <result pre="References 1.TholeyDM, AhnJ. Impact of hepatitis C virus infection on" exact="hepatocellular carcinoma." post="Gastroenterol Clin North Am. 2015;44(4):761–773. doi:10.1016/j.gtc.2015.07.00526600218 2.KayaliZ, SchmidtWN. Finally"/>
  <result pre="antiviral drug development. Antiviral Res. 2015;118:148–158. doi:10.1016/j.antiviral.2015.03.01425842996 4.LindenbachBD, RiceCM. Unravelling" exact="hepatitis" post="C virus replication from genome to function. Nature. 2005;436(7053):933–938."/>
  <result pre="doi:10.1038/nature0407716107832 5.JacobsonIM, McHutchisonJG, DusheikoG, et al. Telaprevir for previously untreated" exact="chronic hepatitis" post="C virus infection. N Engl J Med. 2011;364(25):2405–2416. doi:10.1056/NEJMoa101291221696307"/>
  <result pre="5.JacobsonIM, McHutchisonJG, DusheikoG, et al. Telaprevir for previously untreated chronic" exact="hepatitis" post="C virus infection. N Engl J Med. 2011;364(25):2405–2416. doi:10.1056/NEJMoa101291221696307"/>
  <result pre="DusheikoG, et al. Telaprevir for previously untreated chronic hepatitis C" exact="virus infection." post="N Engl J Med. 2011;364(25):2405–2416. doi:10.1056/NEJMoa101291221696307 6.PoordadF, McConeJJr., BaconBR,"/>
  <result pre="2011;364(25):2405–2416. doi:10.1056/NEJMoa101291221696307 6.PoordadF, McConeJJr., BaconBR, et al. Boceprevir for untreated" exact="chronic" post="HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–1206."/>
  <result pre="7.ShermanKE, FlammSL, AfdhalNH, et al. Response-guided telaprevir combination treatment for" exact="hepatitis" post="C virus infection. N Engl J Med. 2011;365(11):1014–1024. doi:10.1056/NEJMoa101446321916639"/>
  <result pre="AfdhalNH, et al. Response-guided telaprevir combination treatment for hepatitis C" exact="virus infection." post="N Engl J Med. 2011;365(11):1014–1024. doi:10.1056/NEJMoa101446321916639 8.ChayamaK, TakahashiS, ToyotaJ,"/>
  <result pre="daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in" exact="hepatitis" post="C virus genotype 1b-infected null responders. Hepatology. 2012;55(3):742–748. doi:10.1002/hep.2472421987462"/>
  <result pre="LawitzE, et al. Preliminary study of two antiviral agents for" exact="hepatitis" post="C genotype 1. N Engl J Med. 2012;366(3):216–224. doi:10.1056/NEJMoa110443022256805"/>
  <result pre="Med. 2017;376(22):2134–2146. doi:10.1056/NEJMoa161351228564569 12.de LeuwP, StephanC. Protease inhibitor therapy for" exact="hepatitis" post="C virus-infection. Expert Opin Pharmacother. 2018;19(6):577–587. doi:10.1080/14656566.2018.145442829595065 13.GaneE, PoordadF,"/>
  <result pre="ABT-530 treatment in patients with HCV genotype 1 or 3" exact="infection" post="and compensated cirrhosis. Gastroenterology. 2016;151(4):651–659.e651. doi:10.1053/j.gastro.2016.07.02027456384 14.JacobsonIM, LawitzE, GaneEJ,"/>
  <result pre="8 weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in patients with" exact="chronic" post="HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122."/>
  <result pre="grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for" exact="hepatitis" post="C virus genotype 1 infection in previously untreated patients"/>
  <result pre="with or without ribavirin for hepatitis C virus genotype 1" exact="infection" post="in previously untreated patients with cirrhosis and patients with"/>
  <result pre="C virus genotype 1 infection in previously untreated patients with" exact="cirrhosis" post="and patients with previous null response with or without"/>
  <result pre="cirrhosis and patients with previous null response with or without" exact="cirrhosis" post="(C-WORTHY): a randomised, open-label Phase 2 trial. Lancet (London,"/>
  <result pre="and elbasvir (MK-8742) with or without ribavirin in patients with" exact="hepatitis" post="C virus genotype 1 mono-infection and HIV/hepatitis C virus"/>
  <result pre="doi:10.3748/wjg.v20.i26.857225024611 22.LohmannV, KornerF, KochJO, HerianU, TheilmannL, BartenschlagerR. Replication of subgenomic" exact="hepatitis" post="C virus RNAs in a hepatoma cell line. Science."/>
  <result pre="1999;285(5424):110–113. doi:10.1126/science.285.5424.11010390360 23.ZhuZ, WilsonAT, MathahsMM, et al. Heme oxygenase-1 suppresses" exact="hepatitis" post="C virus replication and increases resistance of hepatocytes to"/>
  <result pre="oxidant injury. Hepatology. 2008;48(5):1430–1439. doi:10.1002/hep.2249118972446 24.LindenbachBD, EvansMJ, SyderAJ, et al." exact="Complete" post="replication of hepatitis C virus in cell culture. Science."/>
  <result pre="2008;48(5):1430–1439. doi:10.1002/hep.2249118972446 24.LindenbachBD, EvansMJ, SyderAJ, et al. Complete replication of" exact="hepatitis" post="C virus in cell culture. Science. 2005;309(5734):623–626. doi:10.1126/science.111401615947137 25.ZhuZ,"/>
  <result pre="Science. 2005;309(5734):623–626. doi:10.1126/science.111401615947137 25.ZhuZ, WilsonAT, LuxonBA, et al. Biliverdin inhibits" exact="hepatitis" post="C virus nonstructural 3/4A protease activity: mechanism for the"/>
  <result pre="J Immunol Methods. 1983;65(1–2):55–63. doi:10.1016/0022-1759(83)90303-46606682 28.ZhuZ, MathahsMM, SchmidtWN. Restoration of" exact="type I" post="interferon expression by heme and related tetrapyrroles through inhibition"/>
  <result pre="29.AbdallaMY, BritiganBE, WenF, et al. Down-regulation of heme oxygenase-1 by" exact="hepatitis" post="C virus infection in vivo and by the in"/>
  <result pre="WenF, et al. Down-regulation of heme oxygenase-1 by hepatitis C" exact="virus infection" post="in vivo and by the in vitro expression of"/>
  <result pre="et al. Down-regulation of heme oxygenase-1 by hepatitis C virus" exact="infection" post="in vivo and by the in vitro expression of"/>
  <result pre="infection in vivo and by the in vitro expression of" exact="hepatitis" post="C core protein. J Infect Dis. 2004;190(6):1109–1118. doi:10.1086/jid.2004.190.issue-615319861 30.JiangY,"/>
  <result pre="of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of" exact="hepatitis" post="C virus (HCV) NS3/4A protease. J Med Chem. 2014;57(5):1753–1769."/>
  <result pre="LohmannV, RutterG, KurpanekK, BartenschlagerR. Characterization of cell lines carrying self-replicating" exact="hepatitis" post="C virus RNAs. J Virol. 2001;75(3):1252–1264. doi:10.1128/JVI.75.3.1252-1264.200111152498 32.StuyverLJ, McBrayerTR,"/>
  <result pre="2001;75(3):1252–1264. doi:10.1128/JVI.75.3.1252-1264.200111152498 32.StuyverLJ, McBrayerTR, TharnishPM, et al. Dynamics of subgenomic" exact="hepatitis" post="C virus replicon RNA levels in Huh-7 cells after"/>
  <result pre="to nucleoside antimetabolites. J Virol. 2003;77(19):10689–10694. doi:10.1128/JVI.77.19.10689-10694.200312970456 33.ShangL, LinK, YinZ." exact="Resistance" post="mutations against HCV protease inhibitors and antiviral drug design."/>
  <result pre="antiviral drug design. Curr Pharm Des. 2014;20(5):694–703. doi:10.2174/1381612811319999000823688081 34.PawlotskyJ-M. New" exact="hepatitis" post="C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176–1192."/>
  <result pre="and challenges. Gastroenterology. 2014;146(5):1176–1192. doi:10.1053/j.gastro.2014.03.00324631495 35.SerreSBN, JensenSB, GhanemL, et al." exact="Hepatitis" post="C virus genotype 1 to 6 protease inhibitor escape"/>
  <result pre="selection, fitness, and resistance patterns in the context of the" exact="infectious" post="viral life cycle. Antimicrob Agents Chemother. 2016;60(6):3563–3578. doi:10.1128/AAC.02929-1527021330 36.SorboMC,"/>
  <result pre="fitness, and resistance patterns in the context of the infectious" exact="viral" post="life cycle. Antimicrob Agents Chemother. 2016;60(6):3563–3578. doi:10.1128/AAC.02929-1527021330 36.SorboMC, CentoV,"/>
  <result pre="Agents Chemother. 2016;60(6):3563–3578. doi:10.1128/AAC.02929-1527021330 36.SorboMC, CentoV, Di MaioVC, et al." exact="Hepatitis" post="C virus drug resistance associated substitutions and their clinical"/>
  <result pre="clinical relevance: update 2018. Drug Resist Updat. 2018;37:17–39. doi:10.1016/j.drup.2018.01.00429525636 37.LohmannV." exact="Hepatitis" post="C virus cell culture models: an encomium on basic"/>
  <result pre="NS3 protease inhibitor with antiviral effects in humans infected with" exact="hepatitis" post="C virus. Nature. 2003;426(6963):186–189. doi:10.1038/nature0209914578911 39.NgTI, TripathiR, ReischT, et"/>
  <result pre="In vitro antiviral activity and resistance profile of the next-generation" exact="hepatitis" post="C Virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother."/>
  <result pre="2018;62(1):e01620–e016217.29084747 40.TaylorJG, ZipfelS, RameyK, et al. Discovery of the pan-genotypic" exact="hepatitis" post="C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): a component"/>
  <result pre="41.SummaV, LudmererSW, McCauleyJA, et al. MK-5172, a selective inhibitor of" exact="hepatitis" post="C virus NS3/4a protease with broad activity across genotypes"/>
  <result pre="Chemother. 2012;56(8):4161–4167. doi:10.1128/AAC.00324-1222615282 42.StaudingerR, AbrahamNG, LevereRD, KappasA. Inhibition of human" exact="immunodeficiency" post="virus-1 reverse transcriptase by heme and synthetic heme analogs."/>
  <result pre="pigments as HIV-1 protease inhibitors and their effects on HIV-1" exact="viral" post="maturation and infectivity in vitro. Biochem J. 1996;320:681–686. doi:10.1042/bj32006818973584"/>
  <result pre="Dis. 2017;215(suppl_2):S96–S102. doi:10.1093/infdis/jiw42328403438 46.SarrazinC, HezodeC, ZeuzemS, PawlotskyJM. Antiviral strategies in" exact="hepatitis" post="C virus infection. J Hepatol. 2012;56(Suppl 1):S88–S100. doi:10.1016/S0168-8278(12)60010-522300469 47.LoveRA,"/>
  <result pre="doi:10.1093/infdis/jiw42328403438 46.SarrazinC, HezodeC, ZeuzemS, PawlotskyJM. Antiviral strategies in hepatitis C" exact="virus infection." post="J Hepatol. 2012;56(Suppl 1):S88–S100. doi:10.1016/S0168-8278(12)60010-522300469 47.LoveRA, PargeHE, WickershamJA, et"/>
  <result pre="doi:10.1016/S0168-8278(12)60010-522300469 47.LoveRA, PargeHE, WickershamJA, et al. The crystal structure of" exact="hepatitis" post="C virus NS3 proteinase reveals a trypsin-like fold and"/>
  <result pre="of an intestinal heme transporter. Cell. 2005;122(5):789–801. doi:10.1016/j.cell.2005.06.02516143108 52.HalfonP, LocarniniS." exact="Hepatitis" post="C virus resistance to protease inhibitors. J Hepatol. 2011;55(1):192–206."/>
  <result pre="et al. Antiviral activity and hepatoprotection by heme oxygenase-1 in" exact="hepatitis" post="B virus infection. Gastroenterology. 2007;133(4):1156–1165. doi:10.1053/j.gastro.2007.07.02117919491 56.QiuL, FanH, JinW,"/>
  <result pre="Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B" exact="virus infection." post="Gastroenterology. 2007;133(4):1156–1165. doi:10.1053/j.gastro.2007.07.02117919491 56.QiuL, FanH, JinW, et al. miR-122-induced"/>
  <result pre="2010;398(4):771–777. doi:10.1016/j.bbrc.2010.07.02120633528 57.WangS, AveryJE, HannafonBN, LindSE, DingW-Q. Zinc protoporphyrin suppresses" exact="cancer" post="cell viability through a heme oxygenase-1-independent mechanism: the involvement"/>
  <result pre="LindSE, DingW-Q. Zinc protoporphyrin suppresses beta-catenin protein expression in human" exact="cancer" post="cells: the potential involvement of lysosome-mediated degradation. PLoS One."/>
  <result pre="telomerase in human hepatoma cells (abstract #1833). Poster presented at" exact="American" post="Association for Study of Liver Diseases, Annual Meeting; Washington,"/>
  <result pre="(abstract #1833). Poster presented at American Association for Study of" exact="Liver Diseases," post="Annual Meeting; Washington, DC: 1020–24; 2017. 60.IyerJK, ShiL, ShankarAH,"/>
  <result pre="Plasmodium falciparum. Mol Med. 2003;9(5–8):175–182. doi:10.1007/BF0340218214571325 61.CohenRS, WongRJ, StevensonDK. Understanding" exact="neonatal" post="jaundice: a perspective on causation. Pediatr Neonatol. 2010;51(3):143–148. doi:10.1016/S1875-9572(10)60027-720675237"/>
  <result pre="zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor." exact="Cancer" post="Res. 2003;63(13):3567–3574.12839943 63.FangJ, SawaT, AkaikeT, GreishK, MaedaH. Enhancement of"/>
  <result pre="63.FangJ, SawaT, AkaikeT, GreishK, MaedaH. Enhancement of chemotherapeutic response of" exact="tumor" post="cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin."/>
  <result pre="inactivates the RNA polymerase NS5B and suppresses subgenomic replication of" exact="hepatitis" post="C virus. J Biol Chem. 2005;280(10):9049–9057. doi:10.1074/jbc.M41268720015637067 65.YuasaK, NaganumaA,"/>
  <result pre="NaganumaA, SatoK, et al. Zinc is a negative regulator of" exact="hepatitis" post="C virus RNA replication. Liver Int. 2006;26(9):1111–1118. doi:10.1111/liv.2006.26.issue-917032412"/>
 </snippets>
</snippetsTree>
